An independent, public-record investigation into regulatory actions, consumer complaints, and legal proceedings involving MEDVi (medvi.org)
This website presents factual information compiled from publicly available records including FDA enforcement databases, Better Business Bureau profiles, federal and state court filings, published journalism, and official corporate registrations. Every factual claim is accompanied by a source citation. This website does not make legal conclusions or accusations of criminal conduct. The information is presented for consumer education purposes. The author is a consumer who had a personal experience with MEDVi and conducted public-record research. This website constitutes protected speech under the First Amendment and is a good-faith exercise of the right to share factual consumer information. If any fact stated herein is inaccurate, please contact contact@medivi.us for correction.
On February 20, 2026, the U.S. Food and Drug Administration issued Warning Letter #721455 to MEDVi, LLC for misbranding violations under FDCA sections 502(a) and 502(bb).
The FDA cited MEDVi for:
Sources: FDA Press Announcement | STAT News Coverage
MEDVi holds a BBB F rating (the lowest possible) with 361 consumer complaints and a 1.2 out of 5 average customer review score based on 225 reviews. MEDVi is not BBB accredited and has failed to respond to 5 complaints.
Common complaint themes documented in BBB filings include:
Source: BBB Profile — MEDVi (Newark, DE)
As of April 2026, six lawsuits involving MEDVi or affiliated entities have been identified in public court records:
Sources: PACER (Wilson) | Justia (Siuksta) | Justia (Starling) | Chimicles (Day) | UniCourt (Offer Inc.)
Multiple MEDVi pharmacy partners have documented FDA enforcement histories. Consumers should be aware of these publicly available records.
Sources: FDA Warning Letter (Boothwyn) | PhillyVoice Coverage
The FDA removed tirzepatide from the drug shortage list in December 2024 and semaglutide in February 2025. The enforcement discretion period allowing compounding of these drugs has expired.
Under federal law, 503A compounding pharmacies can no longer legally compound "essentially a copy" of commercially available tirzepatide or semaglutide, except in narrow, medically documented cases.
The Day v. OpenLoop/Triad RX class action (Delaware, November 2025) alleges that compounded oral tirzepatide has less than 1% bioavailability without advanced pharmaceutical delivery technology that compounding pharmacies do not possess.
Sources: FDA Compounding Policy | Fierce Healthcare (Class Action)
| Entity | State | Role |
|---|---|---|
| MEDVi, LLC | Delaware | GLP-1 weight loss telehealth (consumer-facing) |
| MEDvidi Inc. | California | Mental health telehealth |
| EZCare Clinic | DBA (FL/CA) | Former ADHD/ESA clinic |
| Mango Clinic | DBA (FL) | Former ESA letter services |
| MEDVIDI HEALTH, P.A. | Florida (filed 3/10/2026) | New entity — filed 18 days after FDA warning |
MEDVi's registered address is 131 Continental Dr, Ste 305, Newark, DE 19713. According to the Offer Inc. v. MEDVi LLC court filing (LA Superior Court, Case 25STCV35544), Matthew Gallagher of Encino, California is identified as CEO and personal guarantor of MEDVi, LLC. Mr. Gallagher does not appear on MEDVi's public marketing materials or website.
MEDVi's technology platform is built by Smart IT, a company registered at Belarus Hi-Tech Park in Minsk, Belarus. Smart IT's CEO, Alex Kulitski, is simultaneously MEDVi's CTO and Co-Founder — a related-party transaction.
Sources: UniCourt (Offer Inc. v. MEDVi) | Crunchbase (Kulitski) | BBB (MEDvidi Inc.)
MEDVi's published cancellation policy states that subscriptions may be canceled by contacting customer service at hello@medvi.org or through the patient portal. The policy describes cancellation as available "at any time for any reason."
Multiple consumers, including the author of this report, have documented that MEDVi chat agents refuse to process cancellation in writing and instead require phone-only cancellation at 585-312-4226, contradicting the published policy. The phone system routes callers through an automated AI system before connecting to a human representative.
The only refund exception is medical disqualification. However, MEDVi charges consumers before any physician consultation occurs. This creates a structural impossibility: consumers cannot obtain medical disqualification (the only refund trigger) because they are charged before the medical evaluation that would determine qualification.
Additionally, MEDVi's medical consent form contains a clause stating that the customer "will not dispute the payments" with their credit card company. Consumer chargeback rights under federal law cannot be waived by merchant contract.
Sources: MEDVi Cancellation Policy | BBB Complaint Records
Futurism reported in May 2025 that MEDVi's website displayed AI-generated deepfake before-and-after photos presented as real patient results, and fabricated media outlet logos (including logos of publications that had not editorially covered MEDVi).
The Offer Inc. v. MEDVi LLC lawsuit (LA Superior Court, December 2025) reveals that MEDVi's affiliate marketing program pays $195 per customer acquisition (CPA). The plaintiff, a Canadian affiliate marketing company, claims it "drove tens of millions of dollars of business per month" to MEDVi and is owed $1,071,715 in unpaid receivables.
On Consumer Affairs, MEDVi's review distribution is bimodal: approximately 55% one-star and 36% five-star reviews, with very few in between. This distribution pattern is recognized by researchers as a potential indicator of review manipulation.
Sources: ConsumerAffairs Reviews | Trustpilot Reviews
OpenLoop Health, MEDVi's clinician network, disclosed a data breach in January 2026 affecting approximately 1.6 million patient records. MEDVi patients who provided personal health information through the platform may have been affected.
Multiple class action lawsuits have been filed in connection with the OpenLoop Health data breach.
Sources: Data Privacy Justice (Breach Investigation) | Prism News (Class Action)
If you have been affected by MEDVi's practices, the following resources may be helpful:
A complete 29-file litigation-ready documentation package is available, including corporate forensics, court records, FDA enforcement documents, pharmacy supply chain analysis, executive background research, and financial structure analysis.
Contact: contact@medivi.us
This report was compiled by A concerned consumer, a consumer in Florida who enrolled in MEDVi on March 30, 2026 and documented his experience. Every factual claim on this website is sourced from publicly available records including FDA databases, BBB profiles, court filings, published journalism, and corporate registrations. This is a personal consumer advocacy website protected under the First Amendment. No statement on this website constitutes legal advice. This website is not affiliated with MEDVi, MEDvidi, or any related entity.
For corrections or inquiries: contact@medivi.us